Folate

For most people, standard folic acid is appropriate and well-evidenced — it's the form used in 95% of the outcome trials including the NTD prevention trials (MRC 1991, Czeizel 1992, PMID 1677062, 1944680). Methylfolate (L-5-MTHF as Metafolin or Quatrefolic) bypasses the DHFR and MTHFR enzymes and produces no unmetabolized folic acid, which is theoretically preferable for MTHFR C677T homozygotes, depression augmentation candidates, and consumers concerned about UMFA. However, clinical outcome data showing methylfolate superiority over folic acid for standard indications like NTD prevention are limited, and folic acid has the vast majority of population-level evidence (PMID 24330831). The practical rule: folic acid for pregnancy NTD prevention and general nutritional adequacy; methylfolate as a reasonable alternative for MTHFR homozygotes, depression augmentation at 7.5–15 mg/day, or individuals specifically concerned about UMFA.

Yes — preconceptional and first-trimester folate is one of the most important nutritional interventions in prenatal medicine. Take 400 mcg folic acid daily (standard prenatal vitamin amount) starting ideally 1–3 months before conception and continuing through the first trimester. High-risk women (prior neural tube defect pregnancy, family history, anticonvulsant use, obesity, diabetes) should take 4 mg/day folic acid. The MRC 1991 trial showed 72% reduction in NTD recurrence with high-dose folic acid; Czeizel 1992 showed similar prevention of first-occurrence NTDs (PMID 1677062, 1944680). Mandatory grain fortification in the US (1998) dropped NTD rates substantially but does not replace individual supplementation — if you could become pregnant, take 400 mcg folic acid daily whether or not you're actively trying to conceive, since the neural tube closes by day 28, often before pregnancy is known.

MTHFR (methylenetetrahydrofolate reductase) is the enzyme that reduces 5,10-methylene-THF to 5-methyl-THF — the active circulating folate form. The C677T polymorphism (rs1801133) reduces enzyme activity to ~30% of wild-type in homozygotes (TT genotype) and ~60% in heterozygotes (CT), and is common: roughly 10–12% of people of European ancestry are TT homozygotes and 40–45% are CT heterozygotes. In folate-replete populations, even TT homozygotes have largely normal homocysteine and folate status; the variant mostly matters when folate intake is marginal. You do NOT need routine MTHFR genetic testing for folate supplementation decisions. If you're worried, take methylfolate (400–800 mcg L-5-MTHF) instead of folic acid; it's a reasonable choice. But clinical outcome data showing methylfolate superiority over folic acid in MTHFR homozygotes are limited, and the 'MTHFR mutation' marketing that pervades alternative medicine is substantially oversold (PMID 24330831).

Not by itself reliably, but L-methylfolate (Deplin or equivalent Metafolin/Quatrefolic at 7.5–15 mg/day) has been studied as adjunct therapy to SSRIs in major depressive disorder with inadequate response to SSRI alone. Papakostas 2012 showed modest but significant improvement in HAM-D scores with L-methylfolate 15 mg/day added to SSRI, with some evidence of greater benefit in patients with MTHFR polymorphisms, elevated inflammatory markers (CRP), or obesity (PMID 23137033). This is psychiatry-directed therapy; activation symptoms (anxiety, irritability, insomnia) can occur at high methylfolate doses and warrant dose reduction. Standard-dose folic acid or folate-containing multivitamins do not treat depression in non-deficient patients. Folate deficiency itself can mimic or worsen depression, so correcting confirmed deficiency is reasonable.

Folate reliably lowers homocysteine by 20–30% in hyperhomocysteinemic patients when combined with B12 and B6. However, the expectation that homocysteine lowering would translate to reduced cardiovascular events was largely disappointed in the major trials — NORVIT, HOPE-2, VISP, SEARCH, and WAFACS all showed no significant reduction in major CV events despite effective homocysteine lowering (PMID 16531614, 17024074). The current view is that homocysteine is mostly a marker rather than a modifiable cause of CV disease, and folate supplementation for cardiovascular prevention in folate-replete populations is not recommended. The Chinese CSPPT trial in folate-deficient hypertensive populations showed some stroke risk reduction (PMID 25713862), suggesting the benefit may be specific to folate-inadequate populations, but for those in fortified countries, meaningful CV benefit from supplemental folate is unlikely.

Yes — this is a real clinical concern. Folate and B12 share the methionine synthase reaction, and folate supplementation can correct the megaloblastic anemia of B12 deficiency without correcting the neurologic damage (peripheral neuropathy, subacute combined degeneration of the spinal cord). The clinical risk is that a patient with early B12 deficiency on folate supplements might have a normal CBC that masks ongoing irreversible neurologic damage. The practical response is to check B12 in any patient with macrocytic anemia before or alongside folate supplementation, and to screen older adults on chronic folate-containing multivitamins periodically for B12 status. Morris 2007 and subsequent analyses suggest the clinical impact of fortification-related masking has been modest but not zero (PMID 17159229). See the Vitamin B12 entry for the full discussion.

Leafy greens (cooked spinach provides ~260 mcg per cup; cooked kale, collards, arugula similar), legumes (cooked lentils ~360 mcg per cup; black beans, chickpeas, pinto beans ~200–300 mcg per cup), asparagus (~134 mcg per 6 spears), broccoli, brussels sprouts, avocado (~120 mcg per cup), citrus fruits (orange ~40 mcg), beef liver (~215 mcg per 3 oz), and fortified grain products. In the US, mandatory fortification adds ~100–200 mcg folic acid per serving of enriched wheat, rice, cornmeal, pasta, and many breakfast cereals. Cooking losses: boiling reduces folate by 50–90% in many green vegetables through leaching into water and oxidation; steaming or brief sautéing preserves folate better. Most omnivores eating any vegetables, legumes, and fortified grains meet the 400 mcg DFE RDA from food, with supplementation needed mainly for pregnancy, deficiency correction, or specific clinical indications.

The adult RDA is 400 mcg DFE/day (for men and non-pregnant women), pregnancy 600 mcg DFE/day, lactation 500 mcg DFE/day, and the tolerable upper limit for synthetic folic acid (not food folate) is 1,000 mcg/day. DFE (dietary folate equivalents) account for the 85% bioavailability of folic acid versus ~50% for food folate: 1 DFE = 1 mcg food folate = 0.6 mcg folic acid consumed with food. For general adult supplementation, 400 mcg folic acid daily in a multivitamin or prenatal is adequate. For pregnancy general-risk, 400–800 mcg. For pregnancy high-risk (prior NTD, anticonvulsants, obesity, diabetes), 4 mg/day. For folate-deficient anemia, 1–5 mg/day for 1–4 months until correction. Going above 1,000 mcg/day folic acid without specific indication is not evidence-supported and carries concerns about B12 masking and theoretical cancer promotion signals.

Yes — and you should. Low-dose weekly methotrexate (for rheumatoid arthritis, psoriasis, IBD, dermatomyositis, etc.) is routinely paired with folic acid 1–5 mg/day to reduce GI toxicity, mouth ulcers, and hepatotoxicity without compromising the therapeutic efficacy of methotrexate. This is standard rheumatology practice, supported by multiple trials. The folate-methotrexate interaction in the rheumatology context is a feature, not a bug — methotrexate's anti-inflammatory effects at low weekly doses are not primarily folate-antagonism-mediated and are preserved. High-dose methotrexate chemotherapy (for osteosarcoma, CNS lymphoma, ALL) is different — folinic acid (leucovorin) rescue is given AFTER methotrexate dosing on a specific timed schedule to reduce toxicity while preserving antitumor effect; folic acid is not adequate for rescue in this context.

Possibly, at doses well above the RDA. Concerns with chronic high-dose folate supplementation (>1,000 mcg/day) include: masking of B12 deficiency with progression of irreversible B12-related neurologic damage; accumulation of unmetabolized folic acid (UMFA) in plasma when DHFR is overwhelmed, with uncertain long-term health implications including theoretical impaired natural killer cell function (PMID 17434895); possible promotion of preneoplastic or neoplastic lesion growth in older adults, per the Aspirin/Folate Polyp Prevention Trial showing increased advanced and multiple colorectal adenomas in participants on 1 mg/day folic acid over years (Cole et al. 2007, PMID 17551128); and observational signals for childhood asthma and possibly autism with very high-dose pregnancy folate (above 4 mg/day), though causality is not established. The practical rule: stay within 400–800 mcg/day for general supplementation, use RDA-range doses unless a specific clinical indication justifies more, and be particularly cautious with long-term high-dose folic acid in older adults with polyp history.